Rgenix is a preclinical stage pharmaceutical company with a mission to develop the world's first cancer therapies designed specifically to target cancer metastasis, the main cause of mortality in cancer patients. Rgenix is leading the revolution in next-generation cancer therapies with first-in-class lead drug candidates for several aggressive cancer subtypes, including Melanoma, Colorectal Cancer, and Triple-Negative Breast Cancer.
In cancer, molecular signals that recruit blood vessels also trigger metastasis
Dr. Sohail Tavazoie: Identifying MicroRNAs That May be Predictors of Metastasis and Chemotherapy-Responsiveness in Colorectal Cancer
Running a Cancer Roadblock
Can molecules determine cancer spread?